Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of KAD-1229 in Type 2 Diabetes
NCT01333592Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mitiglinide in type 2 diabetes mellitus (T2DM), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Incidences of Adverse Events at 52 weeks. Status: completed.
02
Drugs
mitiglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01333592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01333592.